Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients

P. Koralkova, M. Belickova, D. Kundrat, M. Dostalova Merkerova, Z. Krejcik, K. Szikszai, M. Kaisrlikova, J. Vesela, P. Vyhlidalova, J. Stetka, A. Hlavackova, J. Suttnar, P. Flodr, J. Stritesky, A. Jonasova, J. Cermak, V. Divoky

. 2021 ; 13 (9) : . [pub] 20210430

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21017851

Grant support
NV16-33485A MZ0 CEP Register
00023736 Ministry of Health of the Czech Republic
IGA_LF_2020_005 Internal Grant Agency of Palacky University

To better understand the molecular basis of resistance to azacitidine (AZA) therapy in myelodysplastic syndromes (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), we performed RNA sequencing on pre-treatment CD34+ hematopoietic stem/progenitor cells (HSPCs) isolated from 25 MDS/AML-MRC patients of the discovery cohort (10 AZA responders (RD), six stable disease, nine progressive disease (PD) during AZA therapy) and from eight controls. Eleven MDS/AML-MRC samples were also available for analysis of selected metabolites, along with 17 additional samples from an independent validation cohort. Except for two patients, the others did not carry isocitrate dehydrogenase (IDH)1/2 mutations. Transcriptional landscapes of the patients' HSPCs were comparable to those published previously, including decreased signatures of active cell cycling and DNA damage response in PD compared to RD and controls. In addition, PD-derived HSPCs revealed repressed markers of the tricarboxylic acid cycle, with IDH2 among the top 50 downregulated genes in PD compared to RD. Decreased citrate plasma levels, downregulated expression of the (ATP)-citrate lyase and other transcriptional/metabolic networks indicate metabolism-driven histone modifications in PD HSPCs. Observed histone deacetylation is consistent with transcription-nonpermissive chromatin configuration and quiescence of PD HSPCs. This study highlights the complexity of the molecular network underlying response/resistance to hypomethylating agents.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017851
003      
CZ-PrNML
005      
20220509175837.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13092161 $2 doi
035    __
$a (PubMed)33946220
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Koralkova, Pavla $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic
245    10
$a Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients / $c P. Koralkova, M. Belickova, D. Kundrat, M. Dostalova Merkerova, Z. Krejcik, K. Szikszai, M. Kaisrlikova, J. Vesela, P. Vyhlidalova, J. Stetka, A. Hlavackova, J. Suttnar, P. Flodr, J. Stritesky, A. Jonasova, J. Cermak, V. Divoky
520    9_
$a To better understand the molecular basis of resistance to azacitidine (AZA) therapy in myelodysplastic syndromes (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), we performed RNA sequencing on pre-treatment CD34+ hematopoietic stem/progenitor cells (HSPCs) isolated from 25 MDS/AML-MRC patients of the discovery cohort (10 AZA responders (RD), six stable disease, nine progressive disease (PD) during AZA therapy) and from eight controls. Eleven MDS/AML-MRC samples were also available for analysis of selected metabolites, along with 17 additional samples from an independent validation cohort. Except for two patients, the others did not carry isocitrate dehydrogenase (IDH)1/2 mutations. Transcriptional landscapes of the patients' HSPCs were comparable to those published previously, including decreased signatures of active cell cycling and DNA damage response in PD compared to RD and controls. In addition, PD-derived HSPCs revealed repressed markers of the tricarboxylic acid cycle, with IDH2 among the top 50 downregulated genes in PD compared to RD. Decreased citrate plasma levels, downregulated expression of the (ATP)-citrate lyase and other transcriptional/metabolic networks indicate metabolism-driven histone modifications in PD HSPCs. Observed histone deacetylation is consistent with transcription-nonpermissive chromatin configuration and quiescence of PD HSPCs. This study highlights the complexity of the molecular network underlying response/resistance to hypomethylating agents.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Belickova, Monika $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Kundrat, David $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Dostalova Merkerova, Michaela $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Krejcik, Zdenek $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Szikszai, Katarina $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Kaisrlikova, Monika $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic
700    1_
$a Vesela, Jitka $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Vyhlidalova, Pavla $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic
700    1_
$a Stetka, Jan $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic
700    1_
$a Hlavackova, Alzbeta $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Suttnar, Jiri $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Flodr, Patrik $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, 775 15 Olomouc, Czech Republic
700    1_
$a Stritesky, Jan $u Institute of Pathology, First Faculty of Medicine Charles University and General University Hospital, 128 08 Prague, Czech Republic
700    1_
$a Jonasova, Anna $u First Department of Medicine, First Faculty of Medicine Charles University and General University Hospital, 128 08 Prague, Czech Republic
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Divoky, Vladimir $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 9 (2021)
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20220509175834 $b ABA008
999    __
$a ind $b bmc $g 1676442 $s 1138293
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 9 $e 20210430 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a NV16-33485A $p MZ0
GRA    __
$a 00023736 $p Ministry of Health of the Czech Republic
GRA    __
$a IGA_LF_2020_005 $p Internal Grant Agency of Palacky University
LZP    __
$a Pubmed-20210726

Find record

Citation metrics

Archiving options